117 Results for "

myeloid differentiation

" in MedChemExpress (MCE) Product Catalog:
Products (117)

117 Results for "myeloid differentiation" in MCE Product Catalog:

34
34 Publications Verification
Cat. No.: HY-139397
CAS No.: 1357471-57-8
Purity:  99.85%
Target:  

MyD88

Research Areas:  

Cardiovascular Disease

TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway . TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-103483
CAS No.: 111797-22-9
Purity:  99.88%
Research Areas:  

Inflammation/Immunology

MD2-IN-1 is an inhibitor of Myeloid differentiation protein 2 (MD2) with a KD of 189 μM for the recombinant human MD2 (rhMD2).
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-129388B
CAS No.: 2097523-60-7
Purity:  99.64%
Synonyms: CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate
Target:  

Histone Demethylase

Research Areas:  

Inflammation/Immunology Cancer

Pulrodemstat (CC-90011) benzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat benzenesulfonate is less enzymatic inhibition against LSD2, MAO-A, and MAO-B. Pulrodemstat benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N0774
CAS No.: 486-21-5
Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits MMP-7 expression and cell invasion of human hepatoma cells. Isofraxidin inhibits the phosphorylation of ERK1/2 in hepatoma cells . Isofraxidin attenuates the expression of iNOS and COX-2, Isofraxidinalso inhibits TLR4/myeloid differentiation protein-2 (MD-2) complex formation .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-U00435
CAS No.: 1622863-21-1
Research Areas:  

Cancer

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC50 of 18.5 μM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-129388A
CAS No.: 1821307-10-1
Synonyms: CC-90011; LSD1-IN-7
Target:  

Histone Demethylase

Research Areas:  

Inflammation/Immunology Cancer

Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MAO-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B1336
CAS No.: 67-45-8
Furazolidone is a monoamine oxidase (MAO) inhibitor with antiproliferative, apoptosis-inducing and differentiation-promoting activities. Furazolidone may inhibit leukemia fusion protein-mediated bone marrow transformation by upregulating the stability of the tumor suppressor protein p53. Furazolidone exhibits anti-leukemic activity in acute myeloid leukemia (AML) cell lines and can be used for anti-AML research [2].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-129079
CAS No.: 1445700-01-5
Purity:  99.91%
TFMB-(R)-2-HG is a cell membrane-permeable (R)-2-HG and acute myeloid leukemia (AML) oncogenic factor. TFMB-(R)-2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases such as KDM2B and FTO. TFMB-(R)-2-HG impairs cell differentiation in response to Estrogen withdrawal. TFMB-(R)-2-HG is used in acute myeloid leukemia and glioma research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N6985
CAS No.: 27548-93-2
Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-129079A
CAS No.: 1445703-64-9
Purity:  99.79%
Research Areas:  

Endocrinology Cancer

TFMB-(S)-2-HG is a potent TET2 inhibitor. TFMB-(S)-2-HG also inhibits the EglN prolyl hydroxylases. TFMB-(S)-2-HG downregulates Wnt3a, β-catenin (intranuclear) protein expression. TFMB-(S)-2-HG inhibits osteogenic differentiation of cells. TFMB-(S)-2-HG has the potential for the research of acute myeloid leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0559
CAS No.: 52659-56-0
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a Kd value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18948
CAS No.: 1816331-63-1
Research Areas:  

Cancer

GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular α-Hydroxyglutaric acid (2-HG) (HY-113038B), abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-128598
CAS No.: 2249801-12-3
Purity:  99.62%
MD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex antagonist. MD2-TLR4-IN-1 inhibits Lipopolysaccharides (HY-D1056) (LPS)-induced expression of TNF-α and IL-6 in macrophages with IC50 values of 0.89 μM and 0.53 μM, respectively. MD2-TLR4-IN-1 can be used for the study of acute lung injury (ALI) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-100688
CAS No.: 2029049-79-2
Purity:  99.72%
Research Areas:  

Cancer

ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W082785A
CAS No.: 24533-47-9
L6H21, a Chalcone (HY-121054) derivative, is an orally active, potent and specific myeloid differentiation 2 (MD-2) inhibitor. L6H21 directly binds to MD-2 protein with a high affinity and low KD value of 33.3 μM, blocking the formation of the LPS-TLR4/MD-2 complex. L6H21 inhibits LPS-induced expression of TNF-α and IL-6 in RAW264.7 macrophages, with IC50 values of 6.58 and 8.59 μM, respectively. L6H21 can be used for alcoholic liver disease, metabolic disturbance and neuroinflammation research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-126154
CAS No.: 343307-76-6
Purity:  97.13%
Research Areas:  

Inflammation/Immunology

L48H37 is an analog of Curcumin (HY-N0005) with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P75444
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD14; Monocyte differentiation Antigen CD14; CD14 Molecule; CD14 Antigen; myeloid Cell-Specific Leucine-Rich Glycoprotein; My23 Antigen
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P701067
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LY96; Ly-96; Lymphocyte Antigen 96; MD2; MD-2; myeloid differentiation Protein-2; Protein MD-2; MD-2 Mimetic Protein Variant; ESOP-1; ESOP1
Species:  
Human
Source:  
E. coli
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-172158
CAS No.: 140481-05-6
Research Areas:  

Cancer

ALKBH5-IN-5 is a highly selective ALKBH5 (IC50 = 0.62 μM, Kd = 804 nM). ALKBH5-IN-5 disrupts ALKBH5 binding to m 6A-RNA and 6mA-DNA substrates. ALKBH5-IN-5 promotes differentiation, induces apoptosis, cause G2-M phase arrest and exerts strong antiproliferative effects in cancer cells. ALKBH5-IN-5 reduces TACC3 and MYC protein levels and increases cleaved caspase-3 levels. ALKBH5-IN-5 exerts antitumor activity in tumor xenograft mice models. ALKBH5-IN-5 can be used for the research of acute myeloid leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...